Clinico-biologic profile of Langerhans cell histiocytosis: a single institutional study

Indian J Cancer. 2007 Jul-Sep;44(3):93-8. doi: 10.4103/0019-509x.38939.

Abstract

Context: Langerhans cell histiocytosis (LCH) is a rare atypical cellular disorder characterized by clonal proliferation of Langerhans cells leading to myriad clinical presentations and highly variable outcomes. There is a paucity of Indian studies on this subject.

Aim: To present the experience of management of LCH at a single institution.

Settings and design: This is a retrospective observational study of patients with LCH who presented at the Tata Memorial Hospital between January 1987 and December 2002.

Materials and methods: Fifty-two patients with LCH were treated in the study period. Due to the long observation period and variability in diagnostic and therapeutic protocols, the patients were risk-stratified based on present criteria. The disease pattern, management approaches and treatment outcomes of patients were recorded.

Statistical analysis used: Statistical analyses were done using Student's 't' test, test for proportion and survival estimates based on the Kaplan-Meier method.

Results: The median age at presentation was 3 years and more than 48% of the patients had Group I disease. Skeleton, skin and lymphoreticular system were the commonly involved organs. Majority (80%) required some form of therapy. The projected overall survival is 63% at 10 years and mean survival is 118 months. Seventeen percent of surviving patients developed long-term sequelae.

Conclusions: The clinico-biologic profile of LCH patients in India is largely similar to international patterns except a higher incidence of lymphoreticular involvement. Majority of the patients respond favorably to therapy and have a good outcome, except a subset of Group I patients who warrant enrollment in clinical trials with innovative therapeutic strategies to improve outcome.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Histiocytosis, Langerhans-Cell / diagnosis*
  • Histiocytosis, Langerhans-Cell / drug therapy
  • Histiocytosis, Langerhans-Cell / pathology
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Radiotherapy
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents